Recently, HDAC3 inhibitors have been proved to suppress degeneration and improve behavioral performance in multiple neurodegenerative conditions, including Parkinson’s disease (PD), Alzheimer’s disease (AD), Friedreich’s ataxia, spinal cord injury, and ischemic stroke [140–144]. Here, HDAC3 is linked to Parkinson disease.